Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07855133 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Novo Nordisk
268 trials monitored
See 15 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Obesity
3,874 trials monitored
See 152 trials at risk
Type 2 Diabetes
2,231 trials monitored
See 111 trials at risk
The purpose of this clinical study is to find out which zenagamtide dose can be switched to, from maintenance dose of semaglutide in people with overweight or obesity, with or without type 2 diabetes (T2D). All participants will get semaglutide and zenagamtide.
Trial Details
NCT Number NCT07855133
Lead Sponsor Novo Nordisk A/S
Conditions
(from sponsor)		 Overweight, Obesity, Type 2 Diabetes
Related terms Diabetes Mellitus, Type 2, Obesity, Overweight
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov